January 10, 2023 01:57 PM EST

FDA puts Vertex’s new Type 1 diabetes cell therapy IND on hold; Insilico sets up for PhII of AI drug

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Briefly mentioned in Vertex Pharmaceuticals’ JPM presentation Monday, the FDA has put an IND for Vertex’s new Type 1 diabetes cell therapy, VX-264, on hold …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA puts Vertex’s new Type 1 diabetes cell therapy IND on hold; Insilico sets up for PhII of AI drug

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

FDA puts Ver­tex’s new Type 1 di­a­betes cell ther­a­py IND on hold; In­sil­i­co sets up for PhII of AI drug

News Reporter

Senior Reporter

Sign up to read this article for free.

FDA puts Vertex’s new Type 1 diabetes cell therapy IND on hold; Insilico sets up for PhII of AI drug